Spots Global Cancer Trial Database for Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients
Official Title: A Phase 2 Single Arm Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients
Study ID: NCT02159365
Conditions
Study Description
Brief Summary: To explore whether Elotuzumab dose administration over approximately 60 minutes is feasible and safe.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Acrc/Arizona Clinical Research Center, Inc., Tucson, Arizona, United States
Highland Oncology Group, Fayetteville, Arkansas, United States
Comprehensive Blood And Cancer Center, Bakersfield, California, United States
California Cancer Associates for Research and Excellence, Encinitas, California, United States
Compassionate Cancer Res Grp, Fountain Valley, California, United States
Robert A. Moss, Md Facp, Inc., Fountain Valley, California, United States
Loma Linda University Cancer Center, Loma Linda, California, United States
Pacific Cancer Care, Monterey, California, United States
Ventura County Hematology-Oncology Specialists, Oxnard, California, United States
Wellness Oncology & Hematology, West Hills, California, United States
James R. Berenson, MD, Inc., West Hollywood, California, United States
Rocky Mountain Cancer Centers Llp, Denver, Colorado, United States
Cancer Specialists Of North Florida, Jacksonville, Florida, United States
Center For Cancer Care & Research, Lakeland, Florida, United States
Baptist Health Medical Group Oncology, Miami, Florida, United States
Oncology Specialists,S.C, Park Ridge, Illinois, United States
Investigative Clinical Research Of Indiana, Llc, Indianapolis, Indiana, United States
Horizon Oncology Research, Inc, Lafayette, Indiana, United States
Clinical Research Alliance, Inc., New York, New York, United States
St Francis Hospital, Greenville, South Carolina, United States
Greenville Health System, Greenville, South Carolina, United States
Texas Oncology, Dallas, Texas, United States
Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
Local Institution, Houston, Texas, United States
Cancer Centers of South Texas, San Antonio, Texas, United States
Blood & Cancer Center of East Texas, Tyler, Texas, United States
Texas Oncology-McAllen South Second Street, Weslaco, Texas, United States
Blue Ridge Cancer Care, Blacksburg, Virginia, United States
Vista Oncology Inc., PS, Olympia, Washington, United States
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
